that are so technical. These lawsuits (something that the European Commission's Pharmaceutical Inquiry addressed in its report) not only affects governments and generic companies but, above all, consumers. Indeed, as the article states, this linkage as it is generally known and which is unlawful in Europe, has affected as the above article mentions 30 active ingredients and 830 medicinal products. As a result of this unfair practice, Portugal has lost potential savings of 46 to 65 million Euros. This is something that can no longer be accepted.
But these critical moments also create serious temptations for some governments. Price controls and price reductions seem to provide an easy way out to reduce expenditures in medicines. Nevertheless, this medicine may have serious negative side effects for the market. Such measures can distort the market in a way that may make it less attractive thus leading to the eventual reduction in the number of suppliers and potentially to drug shortages -something that is becoming increasingly more familiar also addressed in another article in this issue.
Governments have a critical responsibility to ensure that consumers can have access to the medicines they need at prices they can afford. This is ensured by adopting policies that encourage generic competition in a way that is sustainable over time. Seeking a short-term solution to a structural problem can negatively affect consumers' access to safe and effective medicines.
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